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The effects of dobutamine and intravenous milrinone on 
systemic hemodynamics, coronary blood flow and myo•
cardial metabolism were studied in 11 patients with se•
vere congestive heart failure. Although milrinone and 
dobutamine similarly increased cardiac index from 1.9 
± 0.4 to 2.5 ± 0.4 liters/min per m2 (p < 0.001) and 
from 1.9 ± 0.4 to 2.8 ± 0.8 liters/min per m2 (p < 
0.001), respectively, milrinone decreased left ventricular 
end-diastolic pressure to a greater extent than dobuta•
mine, that is, from 26 ± 6 to 12 ± 8 mm Hg (p < 0.001) 
versus 26 ± 8 to 20 ± 8 mm Hg (p < 0.001). In contrast 
to dobutamine, milrinone significantly reduced mean 
systemic arterial and right atrial pressures. Dobutamine 
increased the first derivative of left ventricular pressure 
(dP/dt) from 1,013 ± 309 to 1,360 ± 538 mm Hg/s 
Milrinone, a new inotropic agent with vasodilator proper•
ties, has a chemical structure similar to that of amrinone. 
Initial reports have demonstrated promising hemodynamic 
effects when milrinone is given intravenously (1) or orally 
(1,2), without many of the side effects of amrinone. How•
ever, any agent with inotropic and vasodilator properties 
has the potential for deleterious effects on myocardial blood 
flow and metabolism, either by causing an excessive in•
crease in myocardial oxygen demand through chronotropic 
and inotropic effects (3,4), or by interfering with myocardial 
blood flow because of a drop in blood pressure (5). The 
present study was designed to evaluate the systemic and 
coronary effects of intravenous milrinone and compare them 
with the effects of dobutamine, a synthetic catecholamine 
with potent beta-adrenergic agonist properties (6,7). 
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(p < 0.01) but milrinone did not. Similarly, blood flow 
and myocardial oxygen consumption were increased by 
dobutamine from 152 ± 87 to 187 ± 118 mVmin (p < 
0.05) and from 17.7 ± 10.9 to 21.5 ± 14.9 ml Oz/min 
(p < 0.05), respectively, but were unchanged by milri•
none. Both drugs significantly decreased coronary vas•
cular resistance and myocardial oxygen extraction but 
did not change myocardial lactate extraction. 
Thus, dobutamine and milrinone produce similar im•
provement in cardiac index. However, dobutamine in•
creases myocardial oxygen consumption, whereas mil•
rinone does not. This difference can probably be explained 
by the substantial vasodilating properties of milrinone. 
(J Am Coil CardioI1986;7:1107-13) 
Methods 
Study patients. The study group consisted of two women 
and nine men (mean age 60 years, range 46 to 74) with 
severe chronic congestive heart failure in New York Heart 
Association functional class III or IV. The cause of heart 
failure was coronary artery disease in seven patients, and 
idiopathic dilated cardiomyopathy in the remaining four. 
Left ventricular ejection fraction averaged 22% (range 9 to 
37). All patients were treated with digitalis and furosemide. 
Eight of the 11 patients were also treated with single or 
combined vasodilator therapy which consisted of long-act•
ing nitrates (Cases 3,4,7,8 and 11), captopril (Cases 4,8 
and 9) and prazosin (Cases 2,10 and 11). The study was 
conducted in the morning and patients had not received any 
cardiac medications for at least 12 hours. All patients signed 
an informed consent form. The protocol was approved by 
the institution's research committee and review board. 
Catheterization procedure. Diagnostic cardiac cathe•
terization, angiography and endomyocardial biopsy (when 
appropriate) were performed before the investigational pro•
cedure. For the study, a micromanometer-tipped catheter 
(Millar PC484A) was inserted into the left ventricular cham•
ber through the right femoral artery, a thermodilution cath-
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eter (Wilton Webster) was inserted into the coronary sinus 
through the right internal jugular vein and a balloon-tipped 
thermodilution catheter was positioned in the pulmonary 
artery through the right femoral vein. To ensure that reflux 
of blood from the right atrium did not interfere with ther•
modilution measurement in the coronary sinus, great care 
was taken to position the coronary sinus thermistor under 
fluoroscopic guidance at least 2 cm beyond the ostium of 
the coronary sinus. In addition, despite elevated right atrial 
pressure in most of the patients, injection of iced saline 
solution into the right atrium for cardiac output determi•
nations did not cause a deflection on the recordings from 
the coronary sinus thermistor. Repeat fluoroscopy was per•
formed at the end of the experimental procedure to ensure 
that catheter position was stable. The experimental proce•
dure was not begun until at least 30 minutes after the last 
injections of contrast material (8). 
Measurements. Measurements included mean and phasic 
right atrial, pulmonary artery and femoral artery pressures, 
peak systolic and end-diastolic left ventricular pressures, 
the first derivative of left ventricular pressure (dP/dt) using 
a micromanometer-tipped catheter (Millar), thermodilution 
cardiac output (in triplicate), coronary sinus blood flow mea•
surements (in duplicate) and arterial and coronary sinus 
blood samples for oxygen content and lactate content. Pres•
sure and flow signals were recorded on an Electronics for 
Medicine VR 12 physiologic recorder. Cardiac output was 
calculated by computer (American Edwards Laboratories 
9520A). Coronary blood flow measurements were done by 
hand and calculated according to the standard formula (9). 
Oxygen content was measured on an Instruments Laboratory 
Table 1. Hemodynamic Effects of Dobutamine 
Mean Right 
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282 cooxymeter. Lactate determinations were performed in 
duplicate on deproteinated blood collected in perchloric acid 
and analyzed using Stat-Pack Rapid Lactate Test Kits (Cal•
biochem-Behring). 
Myocardial oxygen uptake was calculated as arterial ox•
ygen content (ml 02/liter) - coronary sinus oxygen content 
(ml 02/liter). Myocardial oxygen consumption was calcu•
lated as myocardial oxygen uptake (ml 02/liter) x coronary 
blood flow (liters/min). Coronary vascular resistance was 
calculated as mean arterial pressure (mm Hg) - mean right 
atrial pressure (mm Hg) -;- coronary blood flow (mllmin); 
and peripheral vascular resistance as mean arterial pressure 
(mm Hg) - mean right atrial pressure (mm Hg) -;- cardiac 
output (liters/min) x 80. Percent myocardial extraction of 
lactate was calculated as arterial lactate content (mg/dl) -
coronary sinus lactate content (mg/dl) -;- arterial lactate 
content (mg/dl) x 100. 
Protocol. All measurements were performed at base•
line, then repeated after 10 minutes, to ensure that the pa•
tients were hemodynamically stable before drug infusion. 
Administration of dobutamine was begun at 5 JLg/kg per 
min and titrated upward by increments of 3 JLg/kg per min 
at 5 to 10 minute intervals up to a maximal dose of 17 JLg/kg 
per min, unless a maximal cardiac output plateau was reached 
or an undesirable effect was elicited. Adverse effects were 
defined as a 15% increase in heart rate or 15% decrease in 
mean systemic arterial pressure above control valves, or 
both, and development of complex ventricular arrhythmia. 
Milrinone was then administered intravenously in increasing 
bolus doses of 12.5, 25, 50 and 75 JLg/kg, given at 10 
minute intervals to produce a maximal increase in cardiac 
Systemic 
Arterial Atrial Cardiac Vascular 
Heart Rate Pressure LVEDP Pressure Index LV dP/dt Resistance 
(beats/min) (mm Hg) (mm Hg) (mmHg) (mmHg) (mm Hgls) (dynes's-cm- 5) 
Case C D C D C D C D C D C D C D 
I 74 74 69 73 36 33 9 10 1.9 2.3 605 999 1,660 1,400 
2 73 79 68 72 15 11 4 3 1.8 2.1 858 919 1,505 1,380 
3 89 88 86 94 30 10 8 8 1.9 3.1 866 1,238 1,859 1,297 
4 77 87 71 72 25 28 14 12 1.3 1.8 650 771 1,629 1,230 
5 91 92 88 95 35 22 8 5 1.4 2.4 1,044 1,588 2,285 1,565 
6 97 108 75 70 22 16 6 6 2.3 4.6 880 1,348 1,314 609 
7 83 99 82 78 34 30 13 10 1.6 2.7 1,627 1,003 1,903 1,110 
8 86 92 83 85 15 10 5 4 1.8 2.4 848 1,028 1,950 1,472 
9 89 99 105 125 24 20 6 7 2.5 3.4 1,325 2,510 1,616 1,430 
10 101 108 115 118 32 20 3 2 2.7 3.2 1,175 1,425 2,044 1,781 
11 88 113 117 120 21 17 10 10 1.8 2.9 1,272 2,133 2,529 1,579 
Mean 86 94 87 91 26 20 8 7 1.9 2.8 1,031 1,360 1,844 1,350 
±SD 9 12 18 21 8 8 3 3 0.4 0.8 309 538 353 305 
P Value <0.01 <0.05 <0.001 NS <0.001 <0.01 <0.001 
C = control; D = dobutamine; LV dP/dt = first derivative of left ventricular pressure; LVEDP = left ventricular end-diastolic pressure; NS = 
not significant. 
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output without eliciting any of the adverse effects previously 
described. As with dobutamine, only pressures and cardiac 
output were measured at the immediate doses, with all mea•
surements being performed at the maximal tolerated dose 
of milrinone. There were no complications of the catheter 
insertions or dobutamine infusions. One patient (Case 3) 
developed mild, self-limited hypotension and atrial bigem•
iny after a 25 JLg/kg dose of milrinone. 
Statistical analysis. The maximal hemodynamic and 
metabolic effects of dobutamine and intravenous milrinone 
were compared using a two-factor within-subjects analysis 
of variance model. Each patient was observed in the control 
period, during infusion of dobutamine, after return to control 
values and after intravenous administration of milrinone. 
for a total of four observations. In the presence of interaction 
between drugs and time, tests of simple main effects be•
tween the control and treatment periods were made sepa•
rately for each drug to determine the locus of the interaction 
effect. 
Results 
Systemic hemodynamic effects. Administration of do•
butamine at a mean dose of 10 JLg/kg per min (range 8 to 
17) increased cardiac index from 1.9 ± 0.4 to 2.8 ± 0.8 
liters/min per m2 (p < 0.00 1), and decreased left ventricular 
end-diastolic pressure from 26 ± 8 to 20 ± 8 mm Hg (p < 
0.(01). Individual changes are detailed in Table 1. Mean 
systemic arterial pressure and heart rate increased from 87 
± 18 to 91 ± 21 mm Hg (p < 0.05) and from 86 ± 9 to 
94 ± 12 beats/min (p < 0.05), respectively. Left ventricular 
dP/dt increased from 1,013 ± 309 to 1,360 ± 538 mm 
Table 2. Hemodynamic Effects of Milrinone 
Mean Right 
Arlenal Atrial 
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Hg/s (p < 0.01). Systemic vascular resistance fell from 
1,844 ± 353 to 1,350 ± 305 dynes.s-cm- 5 (p < 0.001) 
and right atrial pressure did not change significantly (8 ± 
3 to 7 ± 3 mm Hg). 
Intravenous administration of milrinone at a mean dose 
of 43 JLg/kg (range 25 to 75) increased cardiac index from 
1.9 ± 0.4 to 2.5 ± 0.4 liters/min per m2 (p < 0.(01), and 
decreased left ventricular end-diastolic pressure from 26 ± 
6 to 12 ± 8 mm Hg (p < 0.001). Individual changes 
produced by milrinone are listed in Table 2. Heart rate 
increased from 87 ± 10 to 92 ± 12 beats/min (p < 0.05). 
Mean systemic arterial and right atrial pressures decreased 
from 88 ± 14 to 77 ± 15 mm Hg (p < 0.05) and from 
8 ± 3 to 5 ± 2 mm Hg (p < 0.05), respectively. Systemic 
vascular resistance fell from 1,919 ± 275 to 1,332 ± 350 
dynes.s-cm- 5 (p < 0.001). Left ventricular dP/dt tended to 
increase, although it did not reach statistical significance 
(977 ± 278 to 1,079 ± 264 mm Hg/s). 
When compared with dobutamine, milrinone decreased 
left ventricular end-diastolic and right atrial pressures to a 
greater extent: 12 ± 8 versus 20 ± 8 mm Hg (p < 0.05) 
and 5 ± 2 versus 7 ± 3 mm Hg (p < 0.005), respectively 
(Fig. 1). Similarly, administration of milrinone resulted in 
a lower mean systemic arterial pressure than that noted 
during infusion of dobutamine: 77 ± 5 versus 91 ± 2 mm 
Hg (p < 0.05), whereas dobutamine increased left ventric•
ular dP/dt to a greater extent than milrinone: 1,360 ± 538 
versus 1,079 ± 264 mm Hg/s (p < 0.05). The maximal 
cardiac index produced by dobutamine and milrinone was 
not statistically different: 2.80 ± 0.77 versus 2.46 ± 0.43. 
Coronary hemodynamics and metabolism. During 
administration of dobutamine, coronary sinus blood flow 
Systemic 
Cardiac Vascular 
Heart Rate Pressure LVEDP Pressure Index LV dP/dt Resistance 
(beats/min) (mmHg) (mmHg) (mmHg) (mmHg) (mm Hg/s) (dynes.s-cm - 5) 
Case C M C M C M C M C M C M C M 
74 74 74 65 33 28 \0 4 1.6 2.1 881 1.131 2,048 1,479 
2 71 72 71 62 14 9 4 4 15 1.8 818 783 1,985 1,365 
3 91 82 89 75 30 6 8 7 22 2.7 893 846 1,695 1,157 
4 81 95 75 62 28 21 13 6 1.2 2.7 681 783 1,908 773 
5 92 100 89 80 28 12 8 7 14 1.8 1,044 928 2,400 1,667 
6 \05 109 82 75 29 5 7 5 2.2 3.0 971 1,142 1,500 1,037 
7 83 98 78 68 32 16 II 2 1.8 3.2 661 1,026 1,725 910 
8 84 95 89 73 18 5 6 4 19 2.2 938 965 1,897 1,415 
9 91 92 100 90 28 7 6 6 24 2.7 1,326 1,292 1,600 1,268 
\0 99 \03 115 112 33 15 3 2 2.5 2.8 1,166 1,336 2,243 1,948 
II 85 100 103 88 19 5 \0 6 1.9 2.1 1,374 1,636 2,112 1,637 
Mean 87 92 88 77 26 12 8 5 1.9 2.5 977 1,079 1,919 1,332 
±SD \0 12 14 15 6 8 3 2 0.4 0.4 278 264 275 350 
P Value <0.05 <0.05 <0.001 <0.05 <0.001 NS <0.001 
M = Milrinone; other abbreviations as in Table 1. 
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Figure 1. Comparative effects of dobutamine and in•
travenous milrinone on systemic hemodynamic vari•
ables. Horizontal bars indicate ± SD. * p < 0.05; 
** p < 0.01; *** p < 0.001 versus control. 
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and myocardial oxygen consumption increased from 152 ± 
87 to 187 ± 118 mllmin (p < 0.05) and from 17.7 ± 10.9 
to 21.5 ± 14.9 ml 02/min (p < 0.05), respectively, whereas 
coronary vascular resistance and transcoronary arteriove•
nous oxygen difference decreased from 0.74 ± 0.38 to 0.62 
± 0.35 mm Hg-minlml (p < 0.05) and from 12.2 ± 2.1 
to 11.4 ± 1.8 ml 02/liter (p < 0.05), respectively. Myo•
cardiallactate extraction did not change significantly: 20.6 
± 11.4 versus 16.7 ± 13.7% (NS). Of interest, two patients 
(Cases 8 and 10) had a change from myocardial lactate 
extraction (12 and 8%, respectively) to minimal levels of 
production ( - 1 % extraction each) without evidence of chest 
pain or electrocardiographic changes (Table 3). 
After administration of intravenous milrinone, coronary 
sinus blood flow did not change significantly: 145 ± 86 
versus 164 ± 94 mllmin, whereas coronary vascular re-
Table 3. Coronary Effects of Dobutamine 
A,-C O2 
sistance and arteriovenous oxygen difference decreased from 
0.76 ± 0.39 to 0.58 ± 0.26 mm Hg-min/ml (p < 0.05) 
and from 11.9 ± 2.3 to 10.7 ± 2.8 ml 02/liter (p < 0.05), 
respectively. Myocardial oxygen consumption was un•
changed. Overall, myocardial lactate extraction did not change 
significantly, but in two patients (Cases 3 and 7) lactate 
extraction (33 and 10%, respectively) changed to production 
( - 11 and - 20%, respectively) (Table 4). Neither patient 
had chest pain or electrocardiographic evidence of ischemia, 
and the change in myocardial lactate metabolism in Patient 
3 corresponded to an episode of hypotension produced by 
a dose of 25 /Lg/kg of milrinone. 
Coronary sinus blood flow was lower in patients who 
were treated with intravenous milrinone than in those who 
were treated with dobutamine: 164 ± 94 versus 187 ± 118 
mllmin (p < 0.05), whereas the changes in coronary vas-
CVR 
CSF (mllmin) (ml oxygen/liter) MV02 (ml/min) (mm Hg-min/ml) LE(%) 
Case C D C D C D C D C D 
68 97 9.6 8.9 6.5 8.6 1.47 1.18 19 4 
2 215 202 8.4 9.4 18.1 17.0 0.31 0.36 17 38 
3 305 416 13.0 11.5 39.6 54.6 0.30 0.19 25 21 
4 85 90 14.0 13.6 11.9 13.6 0.88 0.80 12 10 
5 77 98 15.2 13.7 11.7 13.4 1.04 0.92 36 28 
6 103 138 12.1 11.6 12.5 16.0 0.67 0.46 27 17 
7 60 65 12.2 11.4 7.3 7.4 1.15 1.05 8 18 
8 198 160 13.7 12.8 20.3 20.5 0.53 0.51 12 -1 
9 254 340 13.2 11.9 33.5 40.5 0.41 0.37 41 33 
10 155 266 10.2 8.8 15.8 23.4 0.72 0.44 9 -1 
Mean 152 187 12.2 11.4 17.7 21.5 0.74 0.62 12.2 11.4 
±SD 87 118 2.1 1.8 10.9 14.9 0.38 0.35 2.1 1.8 
P Value <0.05 <0.05 <0.05 <0.05 NS 
A, - C O2 = transcoronary arteriovenous oxygen difference; CSF = coronary sinus blood flow; CVR = coronary vascular resistance; LE = 
myocardial lactate extraction; MV02 = myocardial oxygen consumption; other abbreviations as in Tables 1 and 2. 
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Table 4. Coronary Effects of Milrinone 
A,-C O2 
CSF (mJlmin) (mloxygen/liter) 
Case C M C M 
78 95 8.6 8.5 
2 166 148 8.6 8.6 
3 334 357 12.8 120 
4 79 108 14.1 12.0 
5 81 78 15.2 145 
6 128 116 12.3 11.5 
7 60 82 10.8 11.1 
8 132 143 133 11 7 
9 243 276 13.3 11.4 
10 153 237 10.3 4.0 
Mean 145 164 119 10.7 
±SD 86 94 2.3 2.8 
P Value NS <0.05 
M = mIlrinone; other abbreviations as in Tables 1 to 3. 
cular resistance and arteriovenous oxygen difference produced 
by milrinone and dobutamine were similar (Fig. 2). Con•
sequently, while being treated with dobutamine, patients 
had a greater myocardial oxygen consumption than after 
administration of milrinone: 187 ± 118 versus 164 ± 94 
ml 02/liter (p < 0.05) (Fig. 2). 
Discussion 
Hemodynamic effects of milrinone. Conventional 
management of the patient with chronic congestive heart 
failure includes administration of digitalis, diuretic drugs 
and unloading agents. Even with the most vigorous regimen, 
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CVR 
1111 
MV02 (ml/mm) (mm Hg-mm/mIJ LE(%) 
C 
6.7 
146 
42.8 
13.9 
123 
15.7 
73 
17.6 
31.8 
158 
18.3 
10.7 
M C M C M 
8.1 1.56 0.99 24 23 
127 0.42 0.42 29 28 
36.8 026 0.21 33 -11 
128 0.94 0.59 4 
1 J.3 100 0.94 40 18 
13.3 0.59 0.60 37 15 
9.1 1.10 0.80 10 -20 
16.7 0.63 0.48 -8 10 
31 5 0.41 0.33 37 30 
228 0.73 0.46 27 31 
17.5 076 0.58 21 23 
9.8 0.39 0.26 11 16 
NS <005 NS 
there remain a number of patients with an unacceptable level 
of functional impairment. Milrinone is one of the more 
promising new therapeutic agents for patients with refrac•
tory symptoms (1,2). In the present study, intravenous mil•
rinone was shown to improve left ventricular performance 
as evidenced by a rise in cardiac index and a decrease in 
left ventricular filling pressure in patients with severe symp•
toms of heart failure despite optimal chronic therapy. 
Although a positive inotropic effect of milrinone is sug•
gested by the tendency of left ventricular dP/dt to increase, 
another substantial mechanism of the beneficial hemody•
namic effects of milrinone is the direct vasodilation of the 
systemic beds, as evidenced by the marked decline in sys-
i P<O.05
l 
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Figure 2. Comparative effects of dobutamine and in•
travenous mi1rinone on coronary hemodynamics and 
metabolism. Horizontal bars indicate ± SD. * P < 
0.05 versus control. E 
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temic arterial pressure. In addition, the decline in right atrial 
pressure in the face of an increased cardiac output suggests 
dilation of the capacitance vessels. The moderate increase 
in left ventricular dP/dt probably underestimates the positive 
inotropic action of milrinone. Indeed, because left ventric•
ular dP/dt is an index of myocardial contractility, which is 
dependent on the loading conditions of the heart, the con•
comitant decrease in cardiac preload and afterload induced 
by milrinone may have limited the rise in left ventricular 
dP/dt produced by its positive inotropic effect (10,11). 
Moreover, left ventricular dP/dt, which in four patients was 
not increased by the highest tolerated dose of milrinone, 
was higher than control values at intermediate doses (12.5 
and 25 jLg/kg), which had less effect on cardiac preload and 
afterload. Other investigators have been able to demonstrate 
a significant increase in left ventricular dP/dt after intra•
venous administration of milrinone to patients with severe 
chronic heart failure (1). When compared with a pure vaso•
dilator such as nitroprusside, intravenous milrinone was found 
to produce higher cardiac output and left ventricular dP/dt 
for an equivalent reduction in blood pressure, confirming a 
positive inotropic effect of milrinone (12). 
Comparison of milrinone and dobutamine. The 
hemodynamic effects observed in our study with dobuta•
mine are similar to those reported earlier (7-12). Although 
dobutamine exerts direct effect on the peripheral vascular 
bed (13,14) when used clinically in patients with severe 
congestive heart failure, its positive inotropic action pre•
dominates (5,6). The data presented here emphasize how a 
relatively pure inotropic agent, such as dobutamine, affects 
patients with congestive heart failure differently than does 
an agent with positive inotropic and direct vasodilating prop•
erties, such as milrinone. Systemic arterial pressure was 
increased slightly by dobutamine and decreased substan•
tially by milrinone. Although cardiac output was increased 
similarly by both drugs, milrinone decreased left ventricular 
filling pressure to a much greater extent than did dobuta•
mine. In view of the different loading conditions of the 
heart, it is difficult to precisely compare the changes in left 
ventricular dP/dt. Nevertheless, dobutamine appears to exert 
stronger positive inotropic action than milrinone. 
Effects on coronary blood flow and myocardial me•
tabolism. Differences between milrinone and dobutamine 
were also apparent in their effect on coronary flow and 
myocardial metabolism. Dobutamine increased two major 
determinants of myocardial oxygen demand (15-18), ino•
tropic state and heart rate. It most likely did not produce a 
change in the third major determinant of demand, systolic 
wall tension, because the changes it produced in left end•
diastolic and peak systolic pressures were small in magni•
tude and opposite in direction. Thus, it is not surprising that 
dobutamine infusion increased both myocardial oxygen con•
sumption and coronary blood flow. Despite the presence of 
severe multi vessel coronary disease in the majority of the 
lACC Vol 7, No 5 
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patients studied. dobutamine apparently did not cause de•
mand to outstrip supply, as coronary sinus oxygen content 
increased and myocardial oxygen extraction decreased sig•
nificantly. Also, for the group, dobutamine did not produce 
a change in myocardial lactate extraction. Although the 
myocardial lactate extraction ratio became negative ( - 1%) 
in two patients, this small amount of lactate production does 
not definitely prove ischemia, because of the complex re•
lation between myocardial lactate metabolism and the ar•
terial level of lactate and free fatty acid (19) and the vari•
ability inherent in the measurement of lactate. 
Milrinone had somewhat different effects on the major 
determinants of myocardial oxygen consumption. Although 
heart rate and inotropic state increased slightly, there was 
evidence of reduction in left ventricular wall tension because 
end-diastolic pressure and aortic pressure both decreased 
significantly. Thus, the lack of increase in myocardial ox•
ygen consumption and coronary blood flow determined by 
intravenous milrinone is consistent with its postulated ef•
fects on the major determinants of myocardial oxygen de•
mand. Similar to dobutamine, milrinone produced a nar•
rowing of arteriovenous oxygen difference across the coronary 
bed, indicating either a gross improvement in the myocardial 
supply/demand relation or (less likely) arteriovenous shunt•
ing in the coronary bed. For the group, there was no con•
sistent change in myocardial lactate extraction after milri•
none infusion. However, two patients (one during a 
hypotensive episode) did produce lactate after infusion of 
milrinone (extraction ratio - 11 and - 20%, respectively). 
In these two patients, despite the absence of chest pain or 
electrocardiographic changes, it is probable that lactate pro•
duction of this degree was evidence of ischemia. 
Both milrinone and dobutamine produced a significant 
decrease in coronary vascular resistance. As dobutamine 
caused an increase in myocardial oxygen consumption and 
coronary flow, it is difficult to determine how much of the 
decrease in coronary resistance is due to coronary autoreg•
ulation (20,21), and how much to a direct coronary vaso•
dilating effect. However, with milrinone, the decrease in 
coronary vascular resistance was not associated with an 
increase in coronary flow, and probably reflects a direct 
vasodilator effect of the drug. 
Conclusion. Although dobutamine and milrinone produce 
similar increases in cardiac index in patients with refractory 
congestive heart failure, their mechanism of action appears 
to differ. With dobutamine, a predominant positive inotropic 
effect, rather than a direct reduction in arterial impedance, 
is responsible for the increase in cardiac index. In contrast, 
with milrinone, the direct reduction in arterial impedance 
contributes substantially to the increase in cardiac index in 
addition to its positive inotropic effect. Such differences in 
mechanism of action explain why myocardial oxygen con•
sumption is increased by dobutamine and left unchanged by 
milrinone. 
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